AR and prostate cancer: Although AR antagonists can enhance the overall survival rate of prostate cancer patients, inhibition of AR signals can inhibit mitochondrial respiration of myeloid cells through the MPC/AMPK signaling pathway, indirectly enhance glycolysis, and further enhance the tumor-promoting function of MDSCs, leading to tumor progression and death of patients [41].